Physician profile
James Bower
NPI 1588671440
$12,245.48
in general payments reported to CMS, 2019-2025
21 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,531 · 2020: $3,360 · 2021: $806 · 2022: $1,561 · 2023: $666 · 2024: $163 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,916.70 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $802.90 | 2020-2024 | |
| Ucb Sa | $569.69 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $423.91 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.04 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $287.74 | 2019-2023 | Eliquis |
| Abbott Laboratories | $195.18 | 2020-2024 | Perclose Proglide |
| Astrazeneca Pharmaceuticals Lp | $172.86 | 2020-2024 | Farxiga |
| Kestra Medical Technology Services, INC. | $85.61 | 2022 | |
| Pfizer INC. | $57.38 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $55.11 | 2019-2021 | |
| Scpharmaceuticals INC. | $42.70 | 2023 | |
| Novo Nordisk INC | $41.15 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.81 | 2025 | |
| Amgen INC. | $33.22 | 2025 | Repatha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $27.36 | 2024 | Arcalyst |
| Cvrx, INC. | $23.51 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals, Ltd. | $21.82 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $19.65 | 2025 | Verquvo |
| Circa Scientific, INC. | $15.43 | 2025 | |
| Esperion Therapeutics, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.